Funding for this research was provided by:
Melanoma Research Alliance
Sidney Kimmel Comprehensive Cancer Center (P30 CA006973)
(R01 CA142779, K24 CA139052)
National Institutes of Health (UM1 CA154967, IH/NCI Cancer Center Support Grant P30 CA015704, T32 CA193145)
Bloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Cancer Immunotherapy Trials Network
Stand Up To Cancer–Cancer Research Institute Cancer Immunology Translational Cancer Research Grant (SU2C-AACR-DT1012)
Text and Data Mining valid from 2018-10-01
Received: 21 June 2018
Accepted: 6 September 2018
First Online: 1 October 2018
Ethics approval and consent to participate
: Evaluation of archived pathology specimens described in this manuscript is covered under a study approved by the Johns Hopkins University Institutional Review Board which does not require individual patient consent.
: Not applicable.
: EJL: consultant for Bristol-Myers Squibb, EMD Serono, Merck, Novartis; research funding from Bristol-Myers Squibb.RAA: Bristol-Myers Squibb, Merck, Five Prime Therapeutics, Adaptive Biotechnologies.SLT: consultant for Five Prime Therapeutics; stock options from Five Prime Therapeutics; research funding from Bristol-Myers Squibb.JMT: consultant for Bristol-Myers Squibb, Amgen, Merck, AstraZeneca; research funding from Bristol-Myers Squibb
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.